Oncology & Cancer

FDA approves CAR T therapy for large B-cell lymphoma

The U.S. Food and Drug Administration (FDA) has expanded approval for a personalized cellular therapy developed at the University of Pennsylvania's Abramson Cancer Center, this time for the treatment of adult patients with ...

Immunology

Study finds how to shutdown cancer's powerful master protein

The powerful master regulatory transcription factor called Bcl6 is key to the survival of a majority of aggressive lymphomas, which arise from the B-cells of the immune system. The protein has long been considered too complex ...

Oncology & Cancer

DNA sequencing determines lymphoma origin, prognosis

Sequencing tiny bits of DNA circulating in the blood of patients with lymphoma can accurately identify the cancer subtype and pinpoint mutations that might cause drug resistance, according to researchers at the Stanford University ...

Oncology & Cancer

Landmark CAR-T cancer study published

Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

page 1 from 13